Investor Relations


PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.

For Investor Relations inquiries, please contact PureTech's Investor Relations team at:

View our corporate deck

Share Price

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Annual Report 2021


Corporate Presentation 


Cash at Parent Level

$377.9M PureTech Level Cash and Cash Equivalents as of March 31, 2022 1 with an addition of up to ~$115.4M from the
sale of KRTX shares on August 8, 2022, post-period*

Analyst Coverage